<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322048</url>
  </required_header>
  <id_info>
    <org_study_id>110429</org_study_id>
    <nct_id>NCT01322048</nct_id>
  </id_info>
  <brief_title>DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury</brief_title>
  <official_title>DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Severe Traumatic Brain Injury, A Pilot Randomized Clinical Trial Using Propranolol and Clonidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt Institute for Clinical and Translational Research (CTSA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Association for the Surgery of Trauma (EAST)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators intend to determine the effect of adrenergic blockade on 1) short-term
      physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe
      Traumatic Brain Injury (TBI).

      The primary hypothesis is that adrenergic blockade after severe TBI will be associated with
      increased ventilator-free days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe traumatic brain injury (TBI) is associated with sympathetic hyperactivity resulting in
      catecholamine excess, abnormal heart rate variability, agitation and sympathetic storms, deep
      white matter changes, and poor neuropsychological outcomes. Notably, persistent sympathetic
      hyperactivity after TBI results in higher days of mechanical ventilation and longer intensive
      care unit (ICU) length of stay (LOS). While there are data describing limited portions of
      this response, the full spectrum of sympathetic hyperactivity after severe TBI has not been
      systemically described or methodically intervened upon.

      We will perform a double-blinded, randomized, placebo-controlled pilot trial in a 100 patient
      cohort in which one group will receive centrally acting sympatholytic drugs, propranolol and
      clonidine, and the other group, placebo, within 48 hours of severe TBI. The length of therapy
      will be 7 days.

      The primary question studied is whether ventilator-free days will be increased after therapy.

      Secondary endpoints include plasma and urine catecholamine levels, heart rate and blood
      pressure variability, responses to autonomic cold pressor testing, assessments of coma,
      sedation, and agitation, sedative requirements, analgesic use, antipsychotic medication use,
      coma-free days, ventilator-free days, Intensive Care Unit (ICU) length of stay, and survival.
      Also, neuropsychological outcomes will be measured at ICU discharge, 3 months, and 12 months.

      Interim Analysis: At approximately 50% targeted accrual, n=46 randomized subjects, an interim
      analysis will be performed with A Priori (planned) futility and efficacy rules, which are
      DSMB and IRB approved.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free Days</measure>
    <time_frame>Baseline to day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Norepinephrine Levels</measure>
    <time_frame>Post-treatment (t=Day 8)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Brain Injuries</condition>
  <condition>Craniocerebral Trauma</condition>
  <condition>Trauma, Nervous System</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Adrenergic Blockade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol and Clonidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Propranolol and Per Tube Clonidine</intervention_name>
    <description>1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days</description>
    <arm_group_label>Adrenergic Blockade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV q6h and Per Tube q12, both for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 16 years to 64 years

          -  Glasgow Coma Scale score less than or equal to 8 (Severe TBI) with injury on CT

          -  Screen within 24 hours of injury

        Exclusion Criteria:

          -  Pre-existing heart disease (i.e. coronary heart disease)

          -  Pre-existing cardiac dysrhythmia

          -  Allergy to study drugs

          -  Penetrating brain injury

          -  Pre-existing brain dysfunction (i.e. prior severe TBI, debilitating stroke)

          -  Impending brain herniation (i.e. loss of bilateral corneal reflexes)

          -  Craniectomy or craniotomy

          -  Spinal cord injury

          -  Myocardial injury

          -  Severe liver disease

          -  Current use of beta-blockers and/or alpha-2-agonist

          -  Withdrawal of care expected in 24 hours

          -  Prisoners

          -  Pregnant women

          -  Unable to follow-up through final visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayur B Patel, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://medschool.mc.vanderbilt.edu/facultydata/php_files/show_faculty.php?id3=18283</url>
    <description>Principal Investigator</description>
  </link>
  <link>
    <url>http://www.vanderbilthealth.com/traumasurvivors/36172</url>
    <description>Vanderbilt Multidisciplinary Traumatic Brain Injury Clinic (MTBIC)</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>June 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2017</results_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Mayur Patel</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery and Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>Sympathetic Hyperactivity</keyword>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Agitation</keyword>
  <keyword>Severe TBI</keyword>
  <keyword>TBI</keyword>
  <keyword>Catecholamines</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>Adrenergic alpha-Agonists</keyword>
  <keyword>Adrenergic beta-Antagonists</keyword>
  <keyword>Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Trauma, Nervous System</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One subject was enrolled but was not randomized/assigned to either arm, due to a late withdrawal of care decision.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adrenergic Blockade</title>
          <description>Propranolol and Clonidine
IV Propranolol and Per Tube Clonidine: 1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo IV q6h and Per Tube q12, both for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adrenergic Blockade</title>
          <description>Propranolol and Clonidine
IV Propranolol and Per Tube Clonidine: 1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo IV q6h and Per Tube q12, both for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="21" upper_limit="34"/>
                    <measurement group_id="B2" value="27.5" lower_limit="18.5" upper_limit="36"/>
                    <measurement group_id="B3" value="25" lower_limit="19" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ventilator-free Days</title>
        <time_frame>Baseline to day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adrenergic Blockade</title>
            <description>Propranolol and Clonidine
IV Propranolol and Per Tube Clonidine: 1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo IV q6h and Per Tube q12, both for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="5.5" upper_limit="20.1"/>
                    <measurement group_id="O2" value="18.05" lower_limit="0.075" upper_limit="20.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Norepinephrine Levels</title>
        <time_frame>Post-treatment (t=Day 8)</time_frame>
        <population>Of those surviving treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Adrenergic Blockade</title>
            <description>Propranolol and Clonidine
IV Propranolol and Per Tube Clonidine: 1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo IV q6h and Per Tube q12, both for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Norepinephrine Levels</title>
          <population>Of those surviving treatment period</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="962" lower_limit="508" upper_limit="1471"/>
                    <measurement group_id="O2" value="714" lower_limit="391" upper_limit="1257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adrenergic Blockade</title>
          <description>Propranolol and Clonidine
IV Propranolol and Per Tube Clonidine: 1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo IV q6h and Per Tube q12, both for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mayur B. Patel</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6153225000</phone>
      <email>mayur.b.patel@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

